Zai Lab Says New Drug Application for Schizophrenia Treatment Cobenfy Approved by China's National Medical Products Administration

MT Newswires Live

12/23

Zai Lab (ZLAB) said Tuesday that China's National Medical Products Administration has approved its new drug application for Cobenfy for the treatment of schizophrenia in adults.

The approval is supported by the results of a phase 1 and a phase 3 clinical trials in China, as well as three global Emergent clinical trials, the company said.

China Schizophrenia Prevention and Treatment Guidelines already include Cobenfy as a novel treatment for schizophrenia, Zai Lab added.

Shares of the company rose more than 1% in recent pre-bell activity Tuesday.

Price: 17.95, Change: +0.24, Percent Change: +1.36

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2593775490"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593775490\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593775490?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593775490","market":"us","top_or_hot":-1,"title":"Zai Lab Says New Drug Application for Schizophrenia Treatment Cobenfy Approved by China's National Medical Products Administration","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ZAILF\">Zai Lab</a> (ZLAB) said Tuesday that China's National Medical Products Administration has approved its new drug application for Cobenfy for the treatment of schizophrenia in adults.</p><p>The approval is supported by the results of a phase 1 and a phase 3 clinical trials in China, as well as three global Emergent clinical trials, the company said.</p><p>China Schizophrenia Prevention and Treatment Guidelines already include Cobenfy as a novel treatment for schizophrenia, <a href=\"https://laohu8.com/S/ZLAB\">Zai Lab</a> added.</p><p>Shares of the company rose more than 1% in recent pre-bell activity Tuesday.</p><p>Price: 17.95, Change: +0.24, Percent Change: +1.36</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zai Lab Says New Drug Application for Schizophrenia Treatment Cobenfy Approved by China's National Medical Products Administration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZai Lab Says New Drug Application for Schizophrenia Treatment Cobenfy Approved by China's National Medical Products Administration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-23 21:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ZAILF\">Zai Lab</a> (ZLAB) said Tuesday that China's National Medical Products Administration has approved its new drug application for Cobenfy for the treatment of schizophrenia in adults.</p><p>The approval is supported by the results of a phase 1 and a phase 3 clinical trials in China, as well as three global Emergent clinical trials, the company said.</p><p>China Schizophrenia Prevention and Treatment Guidelines already include Cobenfy as a novel treatment for schizophrenia, <a href=\"https://laohu8.com/S/ZLAB\">Zai Lab</a> added.</p><p>Shares of the company rose more than 1% in recent pre-bell activity Tuesday.</p><p>Price: 17.95, Change: +0.24, Percent Change: +1.36</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593775490","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593775490","pubTimestamp":1766495343,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zai Lab  said Tuesday that China's National Medical Products Administration has approved its new drug application for Cobenfy for the treatment of schizophrenia in adults.The approval is supported by the results of a phase 1 and a phase 3 clinical trials in China, as well as three global Emergent clinical trials, the company said.China Schizophrenia Prevention and Treatment Guidelines already include Cobenfy as a novel treatment for schizophrenia, Zai Lab added.Shares of the company rose more than 1% in recent pre-bell activity Tuesday.Price: 17.95, Change: +0.24, Percent Change: +1.36","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4531":"中概回港概念","BK4588":"碎股","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","NHLD":"National Holdings Corporation","ZLAB":"再鼎医药","BK4139":"生物科技","BK4548":"巴美列捷福持仓"},"translate_title":"再鼎医药称治疗精神分裂症新药申请Cobenfy获中国国家药品监督管理局批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NHLD":1.5,"ZLAB":1},"content_text":"Zai Lab (ZLAB) said Tuesday that China's National Medical Products Administration has approved its new drug application for Cobenfy for the treatment of schizophrenia in adults.The approval is supported by the results of a phase 1 and a phase 3 clinical trials in China, as well as three global Emergent clinical trials, the company said.China Schizophrenia Prevention and Treatment Guidelines already include Cobenfy as a novel treatment for schizophrenia, Zai Lab added.Shares of the company rose more than 1% in recent pre-bell activity Tuesday.Price: 17.95, Change: +0.24, Percent Change: +1.36","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}